盐酸妥拉唑林 | 59-97-2

• 物质功能分类: 原料药 - 循环系统用药 - 周围血管扩张药
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 盐酸妥拉唑林
• 中文别名: 苯甲唑啉盐酸盐；2-苄基咪唑啉；2-苄基-2-咪唑啉盐酸盐；盐酸苯甲唑林；苄唑啉；苯甲唑啉；妥拉苏林；2-苄基咪唑啉盐酸盐
• 英文名称: tolazoline hydrochloride
• 英文别名: 2-benzyl-2-imidazoline hydrochloride；2-benzyl-4,5-dihydro-1H-imidazole;hydron;chloride
• CAS: 59-97-2
• 化学式: C₁₀H₁₂N₂*ClH
• mdl: MFCD00012693
• 分子量: 196.68
• InChiKey: RHTNTTODYGNRSP-UHFFFAOYSA-N

物化性质

• 熔点：
  172-176 °C
• 溶解度：
  DMSO（微溶，加热）、甲醇（微溶）
• 碰撞截面：
  135.1 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]
• 稳定性/保质期：
  Hygroscopic

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  24.4
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• TSCA：
  Yes
• 危险品标志：
  Xn
• 安全说明：
  S22
• 危险类别码：
  R22
• 海关编码：
  2933290090
• WGK Germany：
  3
• 危险品运输编号：
  2811
• 储存条件：
  本品应密封保存。

SDS

Name:	Tolazoline Hydrochloride 99% Material Safety Data Sheet
Synonym:	2-Benzyl-2-Imidazoline Hydrochloride
CAS:	59-97-2

Section 1 - Chemical Product MSDS Name:Tolazoline Hydrochloride 99% Material Safety Data Sheet
Synonym:2-Benzyl-2-Imidazoline Hydrochloride

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
59-97-2	Tolazoline Hydrochloride	99%	200-447-3

Hazard Symbols: XN
Risk Phrases: 22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam. Use agent most appropriate to extinguish fire.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 59-97-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: white
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 174.00 - 176.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: freely soluble
Specific Gravity/Density:
Molecular Formula: C10H12N2.HCl
Molecular Weight: 196.72

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 59-97-2: NJ2350000 LD50/LC50:
CAS# 59-97-2: Oral, mouse: LD50 = 400 mg/kg; Oral, rat: LD50 = 1200 mg/kg.
Carcinogenicity:
Tolazoline Hydrochloride - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
Safety Phrases:
S 22 Do not breathe dust.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 59-97-2: No information available.
Canada
CAS# 59-97-2 is listed on Canada's NDSL List.
CAS# 59-97-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 59-97-2 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

Tolazoline HCl 是一种非选择性和竞争性的 α-肾上腺素能受体拮抗剂。

靶点

Target	Value
α-adrenergic receptor

体外研究

Tolazoline 是一种肺血管扩张药，在持续肺动脉高压症的新生儿体内（PPHN）用于减弱肺血管阻力 (PVR)。它具有适度的α-肾上腺素能阻滞活性和组胺激动剂活性，通常用于降低肺动脉压和血管阻力。在所有调查的致痉挛药物中，Tolazoline 没有表现出广泛的SNP作用范围。然而，在人桡动脉中，它可能能够有效抵消 α-肾上腺素能受体介导的血管痉挛。

用途

• 作为血管扩张药
• 用于 α-adrenergic 受体拮抗剂和外周血管扩张剂

类别

有毒物品

毒性分级

高毒

急性毒性

口服 - 大 LD50: 1200 毫克/公斤；口服 - 小鼠 LD50: 400 毫克/公斤

可燃性危险特性

燃烧产生有毒氮氧化物和氯化氢烟雾，同时具有药物副作用，包括心跳加速、出汗、十二指肠出血和溃疡。

储运特性

通风、低温干燥

灭火剂

干粉、泡沫、沙土、二氧化碳、雾状水

反应信息

• 作为反应物：
  描述：

  盐酸妥拉唑林 在 盐酸 、 sodium nitrate 、 二氯甲烷 作用下， 以 phosphate buffer 为溶剂， 以79%的产率得到N-nitrosotolazoline
  参考文献：
  名称：

  重氮盐离子级联反应，来自于含咪唑啉的药物托拉唑啉的亚硝化。

  摘要：

  托拉唑啉（1-苄基咪唑啉）是一种代表性的含咪唑啉的药物，在乙酸中容易与亚硝酸盐反应生成复杂的产物混合物。当使用8倍过量的HNO2时，已鉴定出14种化合物是该转化的产物。包括N-亚硝基酰胺，酯，醇和苯乙酸在内的产品被合理化为由一系列反应性重氮离子产生。当随着转化的进行用CH 2 Cl 2萃取混合物时，可以以高收率从亚硝化反应中分离出N-亚硝基偶氮唑啉。它比托拉唑啉的亚硝化速度快得多（50x），从而得到肟[1-（N-亚硝基-2-咪唑啉基）亚苄基]羟胺，该化合物也可以通过托拉唑啉与异丙基的反应以高收率生产。亚硝酸盐。在低底物和亚硝酸盐浓度下，主要反应产物为N-亚硝基偶氮唑啉，其分解产物N-2-羟乙基苯基乙酰胺，上述肟，苯基乙酸和2-羟乙基苯基乙酸酯。在pH 3.4和37摄氏度下测定了三种缓冲液系统中托拉唑啉的亚硝化率（在0.5 M乙酸盐缓冲液中使用10 * [NO2（-）] = 250时，kobs

  DOI：

  10.1021/tx700317g

文献信息

• 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS
  申请人：Stangeland Eric L.

  公开号：US20110230495A1

  公开（公告）日：2011-09-22

  The invention relates to compounds of formula I: where X, HAr, a, and R 1 through R 6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  本发明涉及如下公式I的化合物： 其中X，HAr，a，以及R1至R6如说明书所述，或其药用可接受的盐。公式I的化合物是5-羟色胺和去甲肾上腺素再摄取抑制剂。本发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的方法和中间体。
• 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS
  申请人：Patterson Lori Jean

  公开号：US20100125092A1

  公开（公告）日：2010-05-20

  The invention relates to compounds of formula I: where a, R 1 , and R 3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  本发明涉及公式I的化合物： 其中a、R1和R3-6如说明书中所定义，或其药用可接受的盐。公式I的化合物是5-羟色胺和去甲肾上腺素再摄取抑制剂。本发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF
  申请人：Soll Mark David

  公开号：US20140080862A1

  公开（公告）日：2014-03-20

  The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives of formula (I): wherein R 3 , R 4 , R 5 , R 6 , R 7 , P, Q, V, W, X, Y, Z and a are as defined in the description, compositions thereof, processes for their preparation and their uses as pesticides.

  本发明涉及新颖的式(I)的芳基咪唑-2-基-氰基乙基氨基衍生物：其中R3、R4、R5、R6、R7、P、Q、V、W、X、Y、Z和a如描述中所定义，以及其组合物、制备方法以及它们作为杀虫剂的用途。
• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。

表征谱图